Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Non-Current Debt: 2022-2025

Historic Non-Current Debt for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $117.6 million.

  • Axsome Therapeutics' Non-Current Debt fell 34.64% to $117.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $117.6 million, marking a year-over-year decrease of 34.64%. This contributed to the annual value of $180.7 million for FY2024, which is 1.48% up from last year.
  • Per Axsome Therapeutics' latest filing, its Non-Current Debt stood at $117.6 million for Q3 2025, which was up 0.09% from $117.5 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Non-Current Debt ranged from a high of $181.4 million in Q1 2025 and a low of $49.3 million during Q1 2022.
  • In the last 3 years, Axsome Therapeutics' Non-Current Debt had a median value of $178.1 million in 2023 and averaged $165.0 million.
  • As far as peak fluctuations go, Axsome Therapeutics' Non-Current Debt spiked by 199.35% in 2023, and later tumbled by 34.64% in 2025.
  • Quarterly analysis of 4 years shows Axsome Therapeutics' Non-Current Debt stood at $94.3 million in 2022, then skyrocketed by 88.92% to $178.1 million in 2023, then grew by 1.48% to $180.7 million in 2024, then tumbled by 34.64% to $117.6 million in 2025.
  • Its Non-Current Debt stands at $117.6 million for Q3 2025, versus $117.5 million for Q2 2025 and $181.4 million for Q1 2025.